Category: Federal Forum Posters
Purpose: Insulin glargine and NPH insulin have similar efficacy and safety profiles, however, the costs between these two insulins differ. The purpose of this medication use evaluation is to evaluate patient characteristics of those with type 2 diabetes mellitus treated with insulin glargine compared to NPH insulin to assess efficacy, which may provide considerations for initiation and transition of therapy for institutional cost-savings potential.
Methods: This medication use evaluation is exempt from the Institutional Review Board. An electronically generated report, utilizing the electronic medical record will be generated over a two year time period, including Veteran patients with type 2 diabetes on twice daily dosing of insulin glargine and NPH insulin who have been on insulin for the past two years. The following data will be collected: insulin type, insulin reservoir, total daily dose, prescriber, age, body mass index (BMI), weight, hemoglobin A1c (HgbA1c), other antidiabetic medications and number of primary care visits addressing diabetes management. To evaluate the impact of patient characteristics of insulin type, analysis will be conducted on a variety of patient characteristics, including: BMI, age, concomitant diabetes medications (orals and injectables), and total daily dose per weight. Efficacy will be evaluated utilizing a surrogate marker of HgbA1c, capturing the average HgbA1c, achievement of HgbA1c less than 7, 7-7.9, 8-8.9, 9-9.9 and greater than or equal to 10 percent, as well as the change in average HgbA1c over a two year time period. Additionally, the amount of primary care visits related to diabetes management and insulin reservoir (vials and pens) will be analyzed to determine how HgbA1c is impacted.
Results: Not Applicable
Conclusion: Not Applicable
Lissette Martinez– PGY1 Pharmacy Resident, Minneapolis VA Health Care System, Minneapolis, MN